FORM 51-102F1

The following management's discussion and analysis ("MD&A") should be read in conjunction with the interim financial statements of Klinik Health Ventures Corp. (the "Company") and notes thereto for the three months ended March 31, 2020. Additional information relating to the Company is available on SEDAR at www.sedar.com.

This MD&A is intended to help the readers understand the Company's interim financial statements for the period from January 1, 2020 to March 31, 2020. The interim financial statements, together with this MD&A are intended to provide the readers with a reasonable basis for assessing the financial performance of the Company as well as forward-looking statements relating to future performance. The interim statements are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The reader should also refer to the Company's audited financial statements and accompanying notes for the period from incorporation to December 31, 2019.

This MD&A was prepared by the management of the Company, reviewed by the Audit Committee and was approved and authorized for issue by the Board of Directors on May 29, 2020. All amounts are in Canadian dollars unless otherwise stated.

Forward-Looking Statements

Certain statements contained in this document constitute "forward-looking statements", including statements relating to the Transaction (as defined below) and certain terms and conditions thereof, the ability of the parties to complete the Transaction, the Consolidation (as defined below), the Exchange Ratio (as defined below), the Resulting Issuer's (as defined below) ability to qualify as a Tier 1 Life Sciences issuer and other statements that are not historical facts. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "propose", "anticipate", "believe", used by any of the Company's management, are intended to identify forward-looking statements. Such statements reflect the Company's forecasts, estimates and expectations, as they relate to the Company's current views based on their experience and expertise with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not intend, and does not assume any obligation to, update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments unless required by applicable securities law.

Description of Business and Overview

The Company was incorporated under the *Business Corporations Act* (Ontario) on April 17, 2019. The Company is classified as a Capital Pool Company ("CPC") under Policy 2.4 of the TSX Venture Exchange (the "Exchange"). As a CPC, the principal business of the Company is the identification and evaluation of assets or a business and, once identified or evaluated, to negotiate an acquisition or participation in a business (the "Qualifying Transaction" or "QT") subject to receipt of shareholders' approval, if required, and acceptance by regulatory authorities.

The Company has not conducted commercial operations other than to enter into discussions for the purpose of identifying a potential QT. On December 3, 2019, the Company completed its initial public offering (the "Offering") of 15,000,000 common shares (the "Shares") at a price of $0.20 per Share, for gross proceeds of $3,000,000 through its agent, Bloom Burton Securities Inc. Following the closing of the Offering, a total of 19,347,500 Shares are issued and outstanding, of which 4,347,500 are currently held in escrow pursuant to the policies of the Exchange.

Beginning in March 2020 the Governments of Canada and Ontario, as well as foreign governments, instituted emergency measures as a result of the COVID-19 virus. The virus has had a major impact on Canadian and international securities and currency markets and consumer activity. As a CPC with no commercial operations, the Company does not anticipate any direct impact on its operations as a result of the COVID-19 virus outbreak. However, this event may adversely delay or affect the Company's ability to complete the Transaction (as defined below). As at May 29, 2020 it is also not possible to accurately quantify or estimate that impact.

Proposed Transaction

On March 20, 2020, the Company entered into a letter of intent (the "LOI") with 2576560 Ontario Inc. operating as NeuPath Health ("NeuPath"), that provides chronic pain management services. The LOI outlines the principal terms and conditions which will result in a reverse takeover of the Company by NeuPath.

Subsequent to the period ended March 31, 2020, the Company entered into an arrangement agreement with NeuPath dated as of April 24, 2020 (the "Arrangement Agreement"). Pursuant to the Arrangement Agreement, the Company will acquire indirectly all of the issued and outstanding common shares of NeuPath ("NeuPath Shares") in consideration for Shares (together with the related transactions and corporate procedures set out in the Arrangement Agreement, the "Transaction"). Refer to the section entitled "*Subsequent Events – Qualifying Transaction*" of this MD&A for additional information.

The registered and head office of the Company is located at Suite 5300, 66 Wellington Street West, Toronto, ON M5K 1E6.

Selected Financial Information

The following selected financial data is derived from the interim financial statements of the Company, prepared in accordance with IFRS as issued by the IASB and interpretations of the IFRS Interpretation Committee.

Selected Statement of Financial Position Data		**As at March 31, 2020**	**As at December 31, 2019**
Net working capital	$	2,895,826	2,963,950
Total current assets	$	2,990,851	3,021,057
Total current liabilities	$	95,025	57,107
Total shareholders' equity	$	2,895,826	2,963,950

Selected Statement of Loss and Comprehensive Loss Data		**Three months ended March 31, 2020**	**From Incorporation to December 31, 2019**
Revenue	$	Nil	Nil
Expenses			
Professional fees, filing fees and bank charges	$	68,124	33,719
Stock-based compensation	$	10,664	82,029
Net loss and comprehensive loss	$	(78,788)	(115,748)
Basic and diluted loss per share	$	0.005	0.071
Weighted average number of shares outstanding		15,000,000	1,627,907

The Company does not have any operations and will not conduct any business other than the identification and evaluation of business and assets for potential acquisition under a Qualifying Transaction.

Share Capital

Authorized share capital:

- Unlimited number of common voting shares.
- Unlimited number of non-voting preferred shares.

(a) Shares

No Shares were issued during the period from January 1, 2020 to March 31, 2020.

Escrowed shares

Certain of the issued and outstanding Shares are subject to a CPC Escrow Agreement. Under the CPC Escrow Agreement, 10% of the escrowed Shares will be released from escrow on the issuance of the Final Exchange Bulletin (the "Initial Release") and an additional 15% are to be released on the dates that are 6, 12, 18, 24, 30 and 36 months following the Initial Release. All Shares issued on the exercise of stock options granted to directors, officers and non-employees prior to the completion of a QT must also be deposited in escrow until the Initial Release is issued. In addition, all Shares of the Company acquired in the secondary market prior to the completion of a QT by any person or company who becomes a control person are required to be deposited in escrow. The release of the Shares held in escrow is contingent on the QT occurring, which means that the Shares meet the definition of contingently returnable shares subject to recall. Subject to certain exemptions permitted by the Exchange, all securities of the Company held by principals of the resulting issuer are also to be escrowed. The Exchange may delist the Company's Shares where the Company has failed to complete a QT within 24 months of the date of listing. Delisting of the Shares would result in the return and cancellation of all of the currently issued and outstanding seed Shares for no consideration.

(b) Options

The Company has established a stock option plan for its directors, officers and consultants under which the Company may grant options from time to time to acquire a maximum of 1,395,000 outstanding Shares. The exercise price of each option granted under the plan shall be determined by the Board of Directors. The plan is to encourage ownership of Shares by directors, senior officers and consultants of the Company. The fair value of the options is measured as of the grant date, using the BSM, and is recognized over the vesting period. The fair value is recognized as an expense with a corresponding increase in contributed surplus. The amount recognized as expense is adjusted to reflect the number of share options expected to vest. Options may be granted for a maximum term of five years from the date of the grant. They are exercisable as determined by the Directors when the option is granted. Options expire within 90 days of termination of employment or holding office as director or officer of the Company and, in the case of death, expire within a maximum period of one year after such death, subject to the expiry date of the option. Any Shares issued upon exercise of the options prior to the Company completing a QT will be subject to escrow restrictions.

No options were granted during the period from January 1, 2020 to March 31, 2020.

The following table reflects the continuity of stock options:

	Number of Stock Options	Weighted Average Exercise Price ($)
Granted to directors and officers	1,395,000	0.20
Balance, March 31, 2020	1,395,000	0.20

(c) Warrants

No warrants were granted during the period from January 1, 2020 to March 31, 2020.

The following table reflects the continuity of warrants:

	Number of Warrants	Weighted Average Exercise Price ($)
Granted to agents	1,500,000	0.20
Balance, March 31, 2020	1,500,000	0.20

Liquidity, Cash Restriction, and Capital Resources

As at March 31, 2020, the Company had working capital of $2,895,826 and cash of $2,990,851. The Company has not pledged any of its assets as security for loans, or otherwise and is not subject to any debt covenants. The management of the Company believes that it has sufficient cash to meet its ongoing obligations and sufficient further resources to be able to complete the Transaction.

The proceeds raised from the issuance of Shares may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than the lesser of 30% of the gross proceeds from the issuance of shares or $210,000 may be used to cover prescribed costs of administrative and general expenses of the Company. These restrictions apply until completion of a Qualifying Transaction by the Company.

The Company monitors its financial position on a continual basis and updates its expected use of cash resources based on the latest available data.

Related Party Transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or corporate entities. Related parties include the Board of Directors, close family members and enterprises which are controlled by these individuals as well as persons performing similar functions. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Transactions with related parties are incurred in the normal course of business and are measured at the exchange amount, which is the amount of consideration established and approve by the related parties.

No transactions with related parties occurred during the period from January 1, 2020 to March 31, 2020.

Off-Balance Sheet Arrangements

There were no off-balance sheet arrangements including contingencies, commitments or guarantees etc. as at March 31, 2020.

As at March 31, 2020, the Company has $163,874 of losses for tax purposes which are available to reduce future taxable income. $95,749 of the losses will expire in the year ending December 31, 2039**,** and $68,125 of the losses will expire in the year ending December 31, 2040.

Critical Accounting Estimates

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities. The estimates and associated assumptions are based on anticipations and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. There have been no significant judgments made by management in the application of IFRS that have a significant effect on these interim financial statements.

Accounting Policies

The Company adopted all significant accounting policies during the interim period in accordance with IFRS requirements. Accounting policies adopted and disclosed in note 3 of the interim financial statements are applied consistently.

Adoption of new standards

On January 1, 2020, the Company adopted amendments to IAS 1 and IAS 8 that are effective for annual periods beginning on January 1, 2020. Amendments to IAS 1 make the definition of material easier to understand and are not intended to alter the underlying concept of materiality in IFRS Standards. The concept of "obscuring" material information with immaterial information has been included as part of the new definition. The threshold for materiality influencing users has been changed from "could influence" to "could reasonably be expected to influence".

The definition of material in IAS 8 has been replaced by a reference to the definition of material in IAS 1. In addition, the IASB amended other Standards and the Conceptual Framework that contain a definition of material or refer to the term "material" to ensure consistency. There was no material impact on the Company's financial statements as a result of adoption of these amendments.

Disclosure of Outstanding Share Data

As at the date of this MD&A, the following is a description of the outstanding equity securities and convertible securities previously issued by the Company:

Shares and Options	**Authorized**	**Outstanding as at May 29, 2020**
Voting or equity securities issued and outstanding	Unlimited common voting shares	19,347,500 issued Shares (see *Share Capital s*ection above)
	Unlimited number of non-voting preferred shares.	None.
Securities convertible or exercisable into voting or equity securities – stock options – granted to directors, officers or consultants	Options to be issued may not exceed 1,934,750 Shares	1,934,750 to purchase Shares in same number at a price of $0.20 per Share. Options may be exercised until December 3, 2024 or April 9, 2025.
Securities convertible or exercisable into voting or equity securities – warrants – granted to Agents	Agents' non-transferable warrants to purchase up to 1,500,000 Shares at a price of $0.20 per Share. These are to be exercised until December 3, 2021	1,500,000 warrants to agents and sub-agents to purchase Shares in same number at a price of $0.20 per Share. These are to be exercised until December 3, 2021

Financial Instruments and Other Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

i) Financial assets

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income (OCI) or through profit or loss); and
- those to be measured subsequently at amortized cost.

The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses are either recorded in profit or loss or OCI.

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in profit or loss.

Subsequent measurement of financial assets depends on their classification. There are three measurement categories under which the Company classifies its financial assets:

- Amortized cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment that is subsequently measured at amortized cost is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included as finance income using the effective interest rate method.

- Fair value through OCI ("FVOCI"): Debt instruments that are held for collection of contractual cash flows and for selling the debt instruments, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains and losses, interest revenue, and foreign exchange gains and losses which are recognized in profit or loss. When the debt instrument is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains (losses). Interest income from these debt instruments is included as finance income using the effective interest rate method.

- Fair value through profit or loss: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVTPL. A gain or loss on an investment that is subsequently measured at FVTPL is recognized in profit or loss and presented net as revenue in the statement of loss and comprehensive loss in the period in which it arises.

The Company classifies cash as financial asset measured at FVTPL. At present, the Company does not have other financial assets.

ii) Financial liabilities

A financial liability is classified as at FVTPL if it is classified as held-for-trading or is designated as such on initial recognition. Directly attributable transaction costs are recognized in profit or loss as incurred. The fair value changes to financial liabilities at FVTPL are presented as follows: where the Company optionally designates financial liabilities at FVTPL the amount of change in the fair value that is attributable to changes in the credit risk of the liability is presented in OCI; and the remaining amount of the change in the fair value is presented in profit or loss. The Company does not designate any financial liabilities at FVTPL.

Other non-derivative financial liabilities are initially measured at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Currently, the Company classifies all of its financial liabilities as held at amortized cost. These financial liabilities are classified as current liabilities as the payment is due within 12 months.

(iii) Fair value hierarchy of financial instruments:

Financial instruments recorded at fair value on the financial statements are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices);

Level 3 – valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's financial instruments consist of cash and cash equivalents.

The carrying amount of financial assets measured at fair value total $2,990,851.

The Company is exposed to various risks through its financial instruments and has a comprehensive risk management framework to monitor, evaluate and manage these risks. The following analysis provides information about the Company's risk exposure and concentration as of March 31, 2020.

Risk disclosures and fair values

The Company's financial instruments, consisting of cash and accounts payable and accrued liabilities, approximate fair values due to the relatively short-term maturities of the instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Liquidity risk

Liquidity risk is the risk that the Company is not able to meet its financial obligations as they become due or can do so only at excessive cost. As at March 31, 2020, the Company had accounts payable and accrued liabilities of $95,025 due within 12 months and had cash of $2,990,851 to meet its current obligations. As a result, the Company has minimal liquidity risk.

Credit risk

Credit risk is the risk of loss associated with the counterparty's inability to fulfill its payment obligations. The Company believes it has no significant credit risk.

Capital Management

The Company's objective when managing capital is to maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. The Company includes share capital and deficit in the definition of capital.

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure the additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through the issuance of equity or by securing strategic partners.

The Company is not subject to externally imposed capital requirements other than the cash restriction disclosed in note 4 of the interim financial statements.

Risks and Uncertainties

The Company has a limited history of existence. There can be no assurance that a Qualifying Transaction will be completed. Further equity or debt financing may be required to complete a Qualifying Transaction. There can be no assurance that the Company will be able to obtain adequate financing to continue. The securities of the Company should be considered a highly speculative investment. The following risk factors should be given special consideration when evaluating an investment in any of the Company's securities:

(a) until completion of a Qualifying Transaction, the Company is not permitted to carry on any business other than the identification and evaluation of potential Qualifying Transactions;

(b) the Company has had no business activity and has not acquired any material assets since its incorporation other than cash;

(c) the Company does not have a history of earnings, nor has it paid any dividends and will not generate earnings or pay dividends until at least after the completion of the Qualifying Transaction;

(d) the Company has only limited funds with which to identify and evaluate potential Qualifying Transactions and there can be no assurance that the Company will be able to identify a suitable Qualifying Transaction;

(e) even if a proposed Qualifying Transaction is identified, there can be no assurance that the Company will be able to successfully complete the transaction;

(f) the Qualifying Transaction may be financed in all or part by the issuance of additional securities by the Company and this may result in further dilution to the investor, which dilution may be significant, and which may also result in a change of control of the Company;

(g) there can be no assurance that an active and liquid market for the common shares will develop and an investor may find it difficult to resell its common shares;

(h) if the Company fails to complete a Qualifying Transaction within 24 months of listing, the Exchange could suspend or delist the common shares of the Company and an interim cease trade order may be issued against the Company's securities by an applicable securities commission if its common shares are suspended from trading on or delisted from the Exchange or otherwise; and

(i) the Company competes with other Capital Pool Companies that are seeking suitable Qualifying Transactions. In addition, other Capital Pool Companies may have substantially greater financial and technical resources than the Company.

Management's Responsibility for Financial Information

The Company's financial statements and the other financial information included in this management report are the responsibility of the Company's management and have been examined and approved by the Board of Directors. The interim financial statements were prepared by management in accordance with generally accepted Canadian accounting principles (i.e. IFRS) and include certain amounts based on management's best estimates using careful judgment. The selection of accounting principles and methods is management's responsibility.

Management recognizes its responsibility for conducting the Company's affairs in a manner to comply with the requirements of applicable laws and established financial standards and principles, and for maintaining proper standards of conduct in its activities.

The Board of Directors supervises the interim financial statements and other financial information through its audit committee, which is comprised of a majority of non-management directors. This committee's role is to examine the financial statements and recommend that the Board of Directors approve them, to examine the internal control and information protection systems and all other matters relating to the Company's accounting and finances. In order to do so, the audit committee meets with the external auditors, with or without the Company's management, to review their respective audit plans and discuss the results of their examination. This committee is responsible for recommending the appointment of the external auditors or the renewal of their engagement.

Subsequent Events

(a) Stock option plan amendment

On April 9, 2020, the Company's Board of Directors approved an amendment to the stock option plan to increase the number of common shares reserved for issuance under the Stock Option Plan from 1,395,000 to 1,934,750. The amendment to the stock option plan was approved by the Exchange on April 3, 2020.

(b) Stock options granted

On April 9, 2020, the Company granted 539,750 stock options to certain of its directors and officers. Each stock option allows the holder thereof to acquire one common share of the Company at a price of $0.20 per share. These options vest 25% on each of the first, second, third and fourth anniversary dates of the date of grant.

(c) Qualifying Transaction

On April 24, 2020, the Company entered into the Arrangement Agreement with NeuPath. Pursuant to the Arrangement Agreement, the Company will acquire indirectly all of the issued and outstanding NeuPath Shares in consideration for Shares. It is intended that the Transaction shall constitute the Company's Qualifying Transaction.

The Transaction is subject to, among other things, receipt of the requisite shareholders' approvals of NeuPath, final approval of the Exchange, court approval and standard closing conditions. Subject to the satisfaction of the closing conditions, the parties expect to close the Transaction on or about June 25, 2020.

Upon completion of the Transaction, the Company will carry on with the business and activities of NeuPath (the Company after the completion of the Transaction is referred to herein as the "Resulting Issuer").

The Transaction is to be carried out pursuant to the Arrangement Agreement under a court approved statutory plan of arrangement pursuant to the *Business Corporations Act* (Ontario). The Transaction will require approval by at least 66⅔% of the votes cast by shareholders of NeuPath present at a special meeting of NeuPath shareholders. The Company has entered into customary voting support agreements with certain NeuPath shareholders as well as each of NeuPath's directors and executive officers.

Pursuant to the Arrangement Agreement (i) holders of issued and outstanding NeuPath Shares will receive five (5) Shares for each one (1) NeuPath Share (the "Exchange Ratio") held by them; and (ii) all options and warrants convertible into NeuPath Shares shall be exchanged, based on the Exchange Ratio, for similar securities to purchase common shares of the Resulting Issuer on substantially similar terms and conditions. As a condition of the Transaction, and subject to the approval of the Company's shareholders, the Company will also undertake a share consolidation of Shares (the "Consolidation"). The Consolidation will occur on the basis of one (1) post-Consolidation Share for every five (5) Pre-Consolidation Share that will be issued and outstanding immediately after giving effect to steps (i) and (ii) noted above (the "Consolidated Shares"). The Consolidated Shares will represent all of the issued and outstanding common shares (the "Resulting Issuer Shares") of the Resulting Issuer.

It is anticipated that upon completion of the Transaction, former NeuPath shareholders will hold approximately 86% of the Resulting Issuer Shares and former shareholders of the Company will hold approximately 14% of the Resulting Issuer Shares, on a non-diluted basis.

The completion of the Transaction is subject to a number of conditions precedent, including, without limitation, (i) approval of the Transaction by NeuPath shareholders; (ii) approval by the Company's shareholders of the matters noted above in relation to the Transaction; and (iii) receipt of all required consents, waivers and approvals from the Exchange, the court, and any other securities regulatory authority having jurisdiction.

(d) Refundable Deposit

The Company has agreed to advance a refundable deposit to NeuPath of $225,000 (the "Deposit") subject to the terms and conditions of a refundable deposit agreement entered into as of April 24, 2020 between the Company and NeuPath. The Deposit shall be used by NeuPath solely on expenditures or investments related to the Transaction and for no other purposes. The Deposit was approved by the Exchange and was advanced by the Company to NeuPath on May 12, 2020.

(e) Subsidiary

On April 21, 2020, 2752695 Ontario Inc., a wholly-owned subsidiary of the Company, was incorporated under the *Business Corporations Act* (Ontario) for the purpose of amalgamating with NeuPath pursuant to the terms of the Arrangement Agreement.

Other Information

The policies of the Exchange prohibit Capital Pool Companies from carrying on formal investor relations activities. Corporate communications and investor inquiries are handled by the Directors of the Company. Additional information about the Company is available on SEDAR at www.sedar.com.

CORPORATE INFORMATION

Contact **Head Office** Suite 5300, 66 Wellington Street West, Toronto, ON M5K 1E6 Canada	**Directors** Eva Koci N. Nicole Rusaw Dan Legault Walt Macnee
Auditors Zeifmans LLP 201 Bridgeland Avenue, Toronto, ON M6A 1Y7 Canada	**Audit Committee** Eva Koci Dan Legault Walt Macnee
Bankers Royal Bank of Canada P.O. Box4047 Terminal A Toronto, ON M5W 1L5	**Transfer Agent** TSX Trust Company
Legal Advisor McCarthy Tétrault LLP	